Seeking Alpha
02 Nov 2026, 09:21 UTC · 1h ago
Veeva Systems: Bouncing Back With A Vengeance, Still A 'Buy' Over $300
Impact · against what's priced in
The strong FQ2 results and the securing of all top-20 pharma accounts are positive but largely consistent with current market expectations for the Vault CRM migration. While current growth exceeds full-year guidance, it does not yet provide evidence of a structural re-acceleration in commercial subscription growth that the market is currently discounting.
- VEEV+0.05
Already priced in
- The price assumes
The migration of legacy CRM customers to Vault, with 12 of the top 20 already committed.
Securing the remaining four undecided top-20 biopharma accounts completes a migration path the market already assumed was progressing, eliminating a known churn risk.
What VEEV's price assumes · Sep 23
Search tags
